PIK3CA and breast cancer: Its dysregulation is strongly implicated in BC development (Guerrero-Zotano et al., 2016), and targeting PI3K/AKT pathway components has emerged as a significant therapeutic strategy (Nunnery and Mayer, 2020; Dey et al., 2017; Sharma et al., 2019).